• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Perindopril: first-line treatment for hypertension.

作者信息

Zanchetti A, Desche P

机构信息

Istituto di Clinica Medica Generale e Terapia Medica, Università di Milano, Italy.

出版信息

Clin Exp Hypertens A. 1989;11 Suppl 2:555-73.

PMID:2691129
Abstract

The antihypertensive efficacy and acceptability of perindopril (P) were compared to those of captopril (C), atenolol (A) and a diuretic, hydrochlorothiazide + amiloride (D), in 3 double-blind parallel multicenter studies involving 165, 173, and 165 patients, respectively. Patients with essential hypertension and a supine DBP between 95 and 125 mmHg (mean 103.9, 106.2, and 105.2 mmHg, respectively) after a 1-month placebo period were randomized to P 4 mg once daily (o.d.) and either C 25 mg twice daily, or A 50 mg o.d. or D (hydrochlorothiazide 50 mg + amiloride 5 mg o.d.) and treated for 3 months, with visits at monthly intervals. If necessary, treatment was adjusted at each visit to control BP (supine DBP less than or equal to 90 mm Hg): firstly by doubling the dose and secondly, one month later, by the addition of a second drug, a diuretic in the studies versus C or A, a beta-blocker in the study versus D. At 3 months, BP control on monotherapy in the three studies was achieved in the following proportion of patients: 49% with P vs 49% with C; 55% with P vs 48% with A; 72% with P vs 72% with D. Most of the patients controlled by P received 4 mg, about 15% were controlled with 8 mg. A further percentage of patients was controlled with combination therapy, the combination with a diuretic being more effective with P than with C (26 vs 8%) or A (23 vs 10%) and the combination with a beta-blocker being less effective with P than with D (5 vs 13%). The total percentage of patients controlled was greater with P than with C (75 vs 57%, p = 0.016) or A (78 vs 58%, p = 0.006) and there was no significant difference between P and D (78 vs 84%). The drop-out rate due to side-effects was up to 6% with P, similar to that observed with C (4%), A (5%) and D (5%). Most of the complaints reported with P were minor and non-specific, their incidence being similar to that observed with the other drugs. Cough was reported with both P (1%) and C (2%) as well as with A (1%) and D (1%). Compared to these drugs, the biological acceptability of P was good, no case of renal failure being observed.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

相似文献

1
Perindopril: first-line treatment for hypertension.
Clin Exp Hypertens A. 1989;11 Suppl 2:555-73.
2
[Perindopril: first-line treatment of arterial hypertension].
Arch Mal Coeur Vaiss. 1989 May;82 Spec No 1:63-72.
3
Assessment of antihypertensive efficacy of perindopril: results of double-blind multicenter studies versus reference drugs.培哚普利降压疗效评估:与对照药物对比的双盲多中心研究结果
J Cardiovasc Pharmacol. 1991;18 Suppl 7:S45-9.
4
A double blind comparison of perindopril and atenolol in essential hypertension.培哚普利与阿替洛尔治疗原发性高血压的双盲对照研究。
J Hum Hypertens. 1990 Oct;4(5):547-52.
5
Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: a double-blind multicentre study. The Multicentre Study Group on Treatment Association with Perindopril.培哚普利联合硝苯地平与培哚普利联合氢氯噻嗪治疗轻至重度高血压:一项双盲多中心研究。培哚普利治疗联合多中心研究组。
J Hum Hypertens. 1994 Feb;8(2):145-9.
6
Captopril versus perindopril: a double blind study in essential hypertension.卡托普利与培哚普利对比:原发性高血压的双盲研究
J Hum Hypertens. 1989 Feb;3(1):17-22.
7
Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study.评估地拉普利联合吲达帕胺治疗轻至中度原发性高血压的疗效和耐受性:一项随机、多中心、对照研究。
J Hum Hypertens. 2003 Feb;17(2):139-46. doi: 10.1038/sj.jhh.1001514.
8
Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.培哚普利/吲达帕胺一线联合用药对高血压患者的24小时动态血压监测疗效:REASON研究
Am J Hypertens. 2004 Mar;17(3):245-51. doi: 10.1016/j.amjhyper.2003.11.001.
9
An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.氨氯地平/雷米普利联合用药与氨氯地平单药治疗高血压的18周前瞻性随机双盲多中心研究:氨氯地平/雷米普利联合治疗评估(ATAR)研究
Clin Ther. 2008 Sep;30(9):1618-28. doi: 10.1016/j.clinthera.2008.09.008.
10
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.缬沙坦联合氢氯噻嗪与氨氯地平单药治疗对伴有其他心血管危险因素的高血压患者的疗效及耐受性比较:VAST研究
Clin Ther. 2005 May;27(5):578-87. doi: 10.1016/j.clinthera.2005.05.006.

引用本文的文献

1
Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol.培哚普利在印度高血压合并 2 型糖尿病患者中的降压疗效和耐受性:1 年随机、双盲、平行研究与阿替洛尔比较。
Clin Drug Investig. 1998;16(3):229-40. doi: 10.2165/00044011-199816030-00007.
2
Perindopril. A review of its pharmacokinetics and clinical pharmacology.培哚普利。其药代动力学与临床药理学综述。
Drugs. 1990;39 Suppl 1:49-63. doi: 10.2165/00003495-199000391-00009.
3
The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure.
培哚普利在慢性肾衰竭高血压患者中的药代动力学及其对血清血管紧张素转换酶活性的影响。
Br J Clin Pharmacol. 1992 Jan;33(1):93-9. doi: 10.1111/j.1365-2125.1992.tb04006.x.